The court split the claim construction rulings, giving Alnylam wins on two key terms but rejecting its broader narrowing attempts. The case continues toward trial on infringement and validity, monitor for summary judgment motions and trial dates. ONPATTRO revenue is not immediately at risk, but a future adverse ruling could create royalty obligations or an injunction.
Drug in focus
ALNY drug pipeline →ONPATTRO
● Neutral Named in this court ruling- Impact
- Phase
- Approved (marketed); Phase 3 (APOLLO-B) completed
- Time to market
- Already approved and marketed — FDA approval recorded 2018-08-10; no new indication approval pending in local FDA records.
- Next catalyst
- None dated
What to watchDo not position in ALNY for an ONPATTRO-specific catalyst, there isn't one on the horizon; treat ONPATTRO as a slowly amortizing cash-flow asset whose quarterly revenue lines (Q2 2026 10-Q filed 2026-07-30) are worth watching inside ALNY's earnings for the pace of patient transition to newer franchise drugs. ALNY's mean analyst target of ~$427.61 (observed 2026-07-31) implies the market values the pipeline, not this legacy product, so any trade thesis should hinge on the rest of the portfolio (e.g., cemdisiran) rather than ONPATTRO.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $228.61entry
- T+1 · 3mo ago +6.12%α +5.91% · $242.61
- T+5 · 3mo ago +5.02%α +5.22% · $240.08
- T+20 · 2mo ago +4.70%α +6.45% · $239.36
- T+60 · 6d ago −33.67%α −31.63% · $151.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ONPATTRO. The court adopted constructions favorable to Alnylam on two key terms, defining 'liposome' narrowly as requiring an inner aqueous medium (excluding micelles) and ruling that the phospholipid component must contain no lysophosphatides, while rejecting Alnylam's proposed constructions on other terms. This is an interlocutory ruling that shifts the probability of eventual infringement liability but does not resolve the case, and the mixed outcome limits its immediate market impact.
Court Ruling Details
Key Facts
- The court construed 'liposome' as 'a lipid vehicle having one or more lipid bilayers or aggregates surrounding an inner aqueous medium,' adopting Alnylam's proposed construction.
- The court ruled that 'the phospholipid is not a lysophosphatidylcholine or lysophosphatidylethanolamine' means 'the phospholipid component contains no lysophosphatidylcholine or lysophosphatidylethanolamine,' also adopting Alnylam's construction.
- The court rejected Alnylam's proposed constructions for 'a lipid component' and 'a phospholipid component,' instead adopting modified versions of the University's proposals.
- The court declined to construe 'a neutral charge' and 'encapsulate the siRNA such that greater than 90% of the liposomes encapsulate siRNA,' finding they have plain and ordinary meaning.
- The case concerns Alnylam's drug ONPATTRO, a commercial product, but no damages or injunction were awarded at this stage.
- This is a Markman (claim construction) ruling, an interlocutory order that does not resolve infringement or validity.
Financial Impact
No damages or financial exposure quantified in the ruling. The case concerns ONPATTRO, a commercial RNAi therapeutic, but this is an early-stage claim construction ruling with no monetary award.
Risk Factors
- Case continues toward trial on infringement and validity, no resolution yet.
- Adverse claim constructions on 'lipid component' and 'phospholipid component' leave room for plaintiff's infringement theory.
- If Alnylam ultimately loses, ONPATTRO could face royalty obligations or an injunction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-b0d498de6d-ALNY |
Track record
15 reports on ALNY
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 4/10 Viewing Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers